ArticleJournal of managed care & specialty pharmacyPublished
Cost-per-responder analysis of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone among transplant-eligible patients with newly diagnosed multiple myeloma
Regional connection
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
- Institution
- Johnson & Johnson
- County
- Montgomery County
Publication record
- Type
- Article
- Venue
- Journal of managed care & specialty pharmacy
- Published
- Topic
- Clinical care
- Subject terms
- Humans; Multiple Myeloma; Neoplasm, Residual; Dexamethasone; Antineoplastic Combined Chemotherapy Protocols; Antibodies, Monoclonal; Cost-Benefit Analysis; United States; Male; Bortezomib; Lenalidomide
- PubMed ID
- 40952913
- PubMed Central ID
- PMC12577728
- Open access
- Yes, free to read
- Added to directory
- Source checked